Spironolactone
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
- Spironolactone
- Spironolactone: From an Undocumented Original Indication to Hypotrichosis Simplex of the Scalp
Spironolactone: From an Undocumented Original Indication to Hypotrichosis Simplex of the Scalp
One-Sentence Summary
The original approved indication for spironolactone is not documented in this evidence pack (data gap, pending DrugBank/label lookup). The TxGNN model predicts a possible link to Hypotrichosis Simplex of the Scalp, but this prediction is currently supported by 0 clinical trials and 0 publications — model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in evidence pack (data gap — pending DrugBank query) |
| Predicted New Indication | Hypotrichosis Simplex of the Scalp |
| TxGNN Prediction Score | 99.26% |
| Evidence Level | L5 (model prediction only, no clinical trials or literature) |
| Norway Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for spironolactone in this evidence pack (original_moa = data gap). Based on the rationale text supplied alongside the prediction, spironolactone is known to act as a mineralocorticoid receptor antagonist with anti-androgen activity, and it does have real-world off-label use in androgenetic alopecia — so a general link between spironolactone and hair-related conditions is not implausible on its face.
However, the evidence pack's own mechanistic assessment for this specific prediction is skeptical: hypotrichosis simplex of the scalp is an autosomal dominant, structural/developmental hair follicle disorder that is not androgen-dependent. There is no established biological link between spironolactone's known MOA and this disease's pathophysiology — the connection is assessed as a TxGNN extrapolation based on phenotypic similarity (hair-related outcomes) rather than genuine mechanistic overlap.
A second, lower-ranked prediction (congenital hypotrichosis milia, score 99.04%) shows the same pattern: a rare ectodermal/follicular developmental disorder with no known relationship to mineralocorticoid or anti-androgen pathways. Both predictions in this evidence pack are flagged as lacking mechanistic support beyond the model's statistical association.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Norway Market Information
Spironolactone is currently not marketed in Norway under this evidence pack (0 authorizations, no license records available).
Safety Considerations
Please refer to the package insert for safety information.
(Note: key warnings, contraindications, and DDI data are flagged as blocking/high-severity data gaps — see Conclusion below.)
Conclusion and Next Steps
Decision: Hold
Rationale: Both candidate indications are supported only by TxGNN model scores (L5, no clinical or literature evidence), and the evidence pack's own mechanistic rationale explicitly notes a lack of biological plausibility for the top prediction. In addition, a Blocking data gap (missing TFDA/label warnings and contraindications) prevents the drug from even entering the S1 safety pre-assessment stage.
To proceed, the following is needed:
- TFDA/product label warnings and contraindications (DG001 — Blocking, required for S1 safety screening)
- Mechanism of action data via DrugBank API (DG002 — High severity)
- Documentation of spironolactone's original approved indication(s)
- Independent clinical or preclinical evidence linking spironolactone to hypotrichosis simplex of the scalp, beyond model-derived similarity
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.